ArticleClinical case reports2023

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.

Si-Man Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.